BioSpace News Archive

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced clinical and supply updates on its COVID-19 Vaccine program. New results from a preclinical study of the Company’s COVID-19 variant-specific vaccine candidates showed that the Company’s variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern

Parkview Health’s integration of the Smiths Medical PharmGuard® Infusion Management System enables smart pump programming and auto documentation to improve safety.

Kaiser Permanente study showed that a history of being consistently active was strongly associated with a reduced risk of hospitalization, ICU admission, and death in those with COVID-19

In just 30 months and despite facing a global pandemic, Penn State and collaborating companies have successfully established and advanced the industrial biotechnology ecosystem and talent pipeline at the university.

1Life Healthcare, Inc. (One Medical) (Nasdaq: ONEM) today announced that its first quarter 2021 results will be released on Wednesday, May 12, 2021, after the close of the market

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy® (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.

VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the closing of its initial public offering of 8,625,000 ordinary shares,

A chemical known to protect nerve cells also slows glaucoma, the leading cause of irreversible blindness, results of a new study in rats show.

Kibow Biotech, Inc., today announced that the U.S. Food and Drug Administration (FDA) had approved the Company’s Investigational New Drug Application (IND) for US-APR2020 to treat patients with Chronic Kidney Disease (CKD) stage IV.

Randomized, Placebo-Controlled Phase 2 Study for Swiss Biotech Kinarus’ Orally Administered Lead Candidate KIN001 in Hospitalized COVID-19 Patients